Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) Products under Development by Stage of Development | 7 | 1 |
| Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) Products under Development by Therapy Area | 8 | 1 |
| Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) Products under Development by Indication | 9 | 1 |
| Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) Products under Development by Companies | 12 | 2 |
| Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) Therapeutics Assessment | 14 | 6 |
| Assessment by Monotherapy/Combination Products | 14 | 1 |
| Assessment by Mechanism of Action | 15 | 1 |
| Assessment by Route of Administration | 16 | 2 |
| Assessment by Molecule Type | 18 | 2 |
| Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) Companies Involved in Therapeutics Development | 20 | 3 |
| AbbVie Inc. | 20 | 1 |
| Handok Inc. | 21 | 1 |
| XBiotech USA, Inc. | 22 | 1 |
| Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) Drug Profiles | 23 | 13 |
| ABT-981 Drug Profile | 23 | 1 |
| CV-18C3 Drug Profile | 24 | 2 |
| HL-2351 Drug Profile | 26 | 1 |
| Monoclonal Antibodies to Inhibit IL-1a for Myocardial Infarction and Atherosclerosis Drug Profile | 27 | 1 |
| RA-18C3 Drug Profile | 28 | 2 |
| T2-18C3 Drug Profile | 30 | 1 |
| Xilonix Drug Profile | 31 | 5 |
| Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) Dormant Projects | 36 | 1 |
| Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) Featured News &Press Releases | 37 | 11 |
| Jun 08, 2016: Appoints Trey Benson as New Commercial Head to Lead Strategic Commercial Development for the Companys Extensive Product Portfolio | 37 | 1 |
| May 24, 2016: XBiotech to Present Positive Preliminary Survival Data on Xilonix(TM) at the 18th European Society of Medical Oncology World Congress on Gastrointestinal Cancer | 37 | 1 |
| Apr 19, 2016: XBiotech to Present Pivotal Phase 3 Data on Xilonix at European Society of Medical Oncology s World Congress on Gastrointestinal Cancer | 38 | 1 |
| Apr 04, 2016: European Medicines Agency Grants Accelerated Assessment of Marketing Authorization Application for Xilonix, XBiotech s True Human Therapeutic Antibody Treatment for Advanced Colorectal Cancer | 39 | 1 |
| Mar 23, 2016: XBiotech Announces European Medicines Agency Validates Marketing Authorization Application for Xilonix in the Treatment of Advanced Colorectal Cancer | 39 | 1 |
| Mar 08, 2016: XBiotech Announces Submission of Marketing Authorization Application for Candidate Colorectal Cancer Therapy to European Medicines Agency | 40 | 1 |
| Mar 04, 2016: European Medicines Agency Grants Eligibility for Submission of XBiotech s Marketing Authorization Application | 41 | 1 |
| Mar 02, 2016: XBiotech to Deliver Presentation on Novel Study Design and Phase III Results From European Study on Xilonix During Meeting at the European Parliament | 42 | 1 |
| Jan 21, 2016: XBiotech to Attend and Present at the ASCO 2016 Gastrointestinal Cancers Symposium | 42 | 1 |
| Jan 08, 2016: XBiotech Reports Additional Positive Data From Phase III European Trial of Xilonix in Advanced Colorectal Cancer | 43 | 1 |
| Dec 07, 2015: XBiotech Announces Positive Results in European Phase III Study for Its Breakthrough Therapy for Colorectal Cancer | 44 | 1 |
| Nov 23, 2015: XBiotech Provides Update on Phase III Oncology Study in Europe | 45 | 1 |
| Nov 03, 2015: AbbVie to present abstract on ABT-981 at the American College of Rheumatology Annual Meeting | 46 | 1 |
| Oct 02, 2015: XBiotech Announces Publication of Clinical Results Supporting the Potential of Its True Human Antibody as a Cardiovascular Therapy | 46 | 1 |
| Aug 17, 2015: XBiotech Completes Enrollment for Xilonix Phase III Registration Study in Europe | 47 | 1 |
| Appendix | 48 | 2 |
| Methodology | 48 | 1 |
| Coverage | 48 | 1 |
| Secondary Research | 48 | 1 |
| Primary Research | 48 | 1 |
| Expert Panel Validation | 48 | 1 |
| Contact Us | 48 | 1 |
| Disclaimer | 49 | 1 |